Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity
NCT ID: NCT05006638
Last Updated: 2022-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
62 participants
INTERVENTIONAL
2022-12-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning
NCT04807634
Role of Intralipid in Management of Organophosphorus Poisoning
NCT04393103
To Study the Effects of Lipid Emulsion on Hemodynamics in Organophosphate Compound Poisoning
NCT03564574
Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning
NCT02160548
Fresh Frozen Plasma Transfusion in Acute Organophosphate Poisoning
NCT06256796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
will receive the traditional supportive treatment according to (PCC-ASUH) protocol
Atropine
a drug used as an antidote for some types of pesticides
Toxogonin
a drug used as an antidote for some types of pesticides
Sodium Bicarbonate Powder and ondansetron
standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
case group
will receive the traditional supportive treatment plus administration of ILE (20%) 1.5 ml/kg as a bolus over 2-3 minutes. Followed immediately by an infusion of 20 % lipid emulsion at a rate of 0.25 mL/kg/min. After 3 minutes of this infusion rate, response to the bolus and initial infusion should be assessed. If there has been a significant response, the infusion rate can be adjusted to 0.025 mL/kg/min with monitoring of blood pressure, heart rate, and other available hemodynamic parameters during the infusion with a maximum dose of 10 mL/kg
Lipid Emulsion, Intravenous
Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
Atropine
a drug used as an antidote for some types of pesticides
Toxogonin
a drug used as an antidote for some types of pesticides
Sodium Bicarbonate Powder and ondansetron
standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipid Emulsion, Intravenous
Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
Atropine
a drug used as an antidote for some types of pesticides
Toxogonin
a drug used as an antidote for some types of pesticides
Sodium Bicarbonate Powder and ondansetron
standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant and lactating females.
* Presence of medical diseases (e.g. renal, hepatic, cardiovascular, neurological diseases and chronic pancreatitis.)
* Allergy to soya-, egg-or peanut protein
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aya Sabry Mohamed Mohamed
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aya Sabry Mohamed Mohamed
Assistant lecturer of forensic medicine and clinical toxicology department faculty of medicine Ain shams university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poison Control Center of Ain-Shams University hospitals
Cairo, Abbasya, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD27/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.